Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration
作者:
J. HOTZ,
R. KLEINERT,
T. GRYMBOWSKI,
U. HENNIG,
J. A. SCHWARZ,
期刊:
Alimentary Pharmacology&Therapeutics
(WILEY Available online 1992)
卷期:
Volume 6,
issue 1
页码: 87-95
ISSN:0269-2813
年代: 1992
DOI:10.1111/j.1365-2036.1992.tb00548.x
出版商: Blackwell Publishing Ltd
数据来源: WILEY
摘要:
SUMMARYLansoprazole (AG 1749/CG 4801) is an inhibitor of gastric acid secretion by blocking H+,K+‐ATPase. In this 2:1 randomized, double‐blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out‐patients suffering from uncomplicated duodenal ulcer. After 2 weeks of treatment ulcer healing was confirmed endoscopically in a significantly higher proportion (P= 0.027) of patients treated with lansoprazole (94/174 = 54.0%) compared to patients receiving famotidine (35/90 = 38.9%). Cumulative healing rates after 4 weeks were 91.4% for the lansoprazole group and 83.3% for the famotidine group (P= 0.065). Pain relief and decrease of concomitant antacid consumption during treatment were comparable in both groups. Both compounds were well tolerated. Rates of recurrent duodenal ulcer in the 6 months after trial treatment were 45/158 (28.5%) after lansoprazole, and 18/69 (26.1%) after famot
点击下载:
PDF
(535KB)
返 回